Literature DB >> 23679813

Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer.

Yusuke Ohara1, Tatsuya Oda, Masato Sugano, Shinji Hashimoto, Tsuyoshi Enomoto, Keiichi Yamada, Yoshimasa Akashi, Ryoichi Miyamoto, Akihiko Kobayashi, Kiyoshi Fukunaga, Yukio Morishita, Nobuhiro Ohkohchi.   

Abstract

CD44(+) /CD24(+) /EpCAM(+) cells have been reported to be cancer stem cells in pancreatic cancer; however, the histological and clinical importance of these cells has not yet been investigated. Here we clarified the characteristics of CD44(+) /CD24(+) /EpCAM(+) cells in clinical specimens of pancreatic cancer using immunohistochemical assay. We used surgical specimens of pancreatic ductal adenocarcinoma from 101 patients. In view of tumor heterogeneity, we randomly selected 10 high-power fields per case, and triple-positive CD44(+) /CD24(+) /EpCAM(+) expression was identified using our scoring system. The distribution, histological characteristics, and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) cells were then analyzed. As a result, the distribution of CD44(+) /CD24(+) /EpCAM(+) cells varied widely among the 101 cases examined, and CD44(+) /CD24(+) /EpCAM(+) expression was correlated with poor glandular differentiation and high proliferation. Survival analysis showed that CD44(+) /CD24(+) /EpCAM(+) expression was not correlated with patient outcome; however, CD44(+) /CD24(+) expression appeared to be correlated with poor prognosis. In conclusion, CD44(+) /CD24(+) /EpCAM(+) expression overlapped with poorly differentiated cells and possessed high proliferative potential in clinical pancreatic cancer. In particular, the presence of double-positive CD44(+) /CD24(+) expression seemed to have clinical relevance, associating with poor prognosis.
© 2013 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23679813      PMCID: PMC7657217          DOI: 10.1111/cas.12198

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  43 in total

1.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

2.  Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas.

Authors:  H Wakimoto; M Aoyagi; T Nakayama; G Nagashima; S Yamamoto; M Tamaki; K Hirakawa
Journal:  Cancer       Date:  1996-01-15       Impact factor: 6.860

3.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

4.  Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity.

Authors:  H Akita; H Nagano; Y Takeda; H Eguchi; H Wada; S Kobayashi; S Marubashi; M Tanemura; H Takahashi; H Ohigashi; Y Tomita; O Ishikawa; M Mori; Y Doki
Journal:  Oncogene       Date:  2011-03-14       Impact factor: 9.867

Review 5.  Cancer stem cell: target for anti-cancer therapy.

Authors:  Carol Tang; Beng T Ang; Shazib Pervaiz
Journal:  FASEB J       Date:  2007-07-11       Impact factor: 5.191

6.  Histological and fine structural features of pancreatic ductal adenocarcinomas in relation to growth and prognosis: studies in xenografted tumours and clinico-histopathological correlation in a series of 75 cases.

Authors:  G Klöppel; G Lingenthal; M von Bülow; H F Kern
Journal:  Histopathology       Date:  1985-08       Impact factor: 5.087

7.  Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity.

Authors:  Andrea Sottoriva; Joost J C Verhoeff; Tijana Borovski; Shannon K McWeeney; Lev Naumov; Jan Paul Medema; Peter M A Sloot; Louis Vermeulen
Journal:  Cancer Res       Date:  2010-01-01       Impact factor: 12.701

8.  Identification and expansion of the tumorigenic lung cancer stem cell population.

Authors:  A Eramo; F Lotti; G Sette; E Pilozzi; M Biffoni; A Di Virgilio; C Conticello; L Ruco; C Peschle; R De Maria
Journal:  Cell Death Differ       Date:  2007-11-30       Impact factor: 15.828

9.  Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas.

Authors:  Heike Immervoll; Dag Hoem; Per Øystein Sakariassen; Ole Johnny Steffensen; Anders Molven
Journal:  BMC Cancer       Date:  2008-02-08       Impact factor: 4.430

10.  Influence of pathological tumour variables on long-term survival in resectable gastric cancer.

Authors:  A Cuschieri; I C Talbot; S Weeden
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

View more
  36 in total

1.  Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors.

Authors:  Matthew I Confeld; Babak Mamnoon; Li Feng; Heather Jensen-Smith; Priyanka Ray; James Froberg; Jiha Kim; Michael A Hollingsworth; Mohiuddin Quadir; Yongki Choi; Sanku Mallik
Journal:  Mol Pharm       Date:  2020-07-22       Impact factor: 4.939

2.  Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine.

Authors:  Mao Lin; Yuan-Ying Yuan; Shu-Peng Liu; Juan-Juan Shi; Xin-An Long; Li-Zhi Niu; Ji-Bing Chen; Qiao Li; Ke-Cheng Xu
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-10       Impact factor: 4.553

3.  The FOXO3/PGC-1β signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma.

Authors:  Motofumi Kumazoe; Mika Takai; Shun Hiroi; Chieri Takeuchi; Mai Kadomatsu; Takashi Nojiri; Hiroaki Onda; Jaehoon Bae; Yuhui Huang; Kanako Takamatsu; Shuya Yamashita; Kenji Kangawa; Hirofumi Tachibana
Journal:  J Biol Chem       Date:  2017-05-15       Impact factor: 5.157

4.  Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma.

Authors:  Prajna Paramita Naik; Subhadip Mukhopadhyay; Prashanta Kumar Panda; Niharika Sinha; Chandan Kanta Das; Rajakishore Mishra; Shankargouda Patil; Sujit Kumar Bhutia
Journal:  Cell Prolif       Date:  2017-11-23       Impact factor: 6.831

Review 5.  Cancer stem cells: a systems biology view of their role in prognosis and therapy.

Authors:  Susan D Mertins
Journal:  Anticancer Drugs       Date:  2014-04       Impact factor: 2.248

6.  FOXO3 is essential for CD44 expression in pancreatic cancer cells.

Authors:  M Kumazoe; M Takai; J Bae; S Hiroi; Y Huang; K Takamatsu; Y Won; M Yamashita; S Hidaka; S Yamashita; S Yamada; M Murata; S Tsukamoto; H Tachibana
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

7.  Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors.

Authors:  Safia Salaria; Anna Means; Frank Revetta; Kamran Idrees; Eric Liu; Chanjuan Shi
Journal:  Am J Clin Pathol       Date:  2015-10       Impact factor: 2.493

Review 8.  New insights into pancreatic cancer stem cells.

Authors:  Chinthalapally V Rao; Altaf Mohammed
Journal:  World J Stem Cells       Date:  2015-04-26       Impact factor: 5.326

Review 9.  Pancreatic cancer stem cell markers and exosomes - the incentive push.

Authors:  Sarah Heiler; Zhe Wang; Margot Zöller
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

10.  Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer.

Authors:  Yusuke Ohara; Tatsuya Oda; Masato Sugano; Shinji Hashimoto; Tsuyoshi Enomoto; Keiichi Yamada; Yoshimasa Akashi; Ryoichi Miyamoto; Akihiko Kobayashi; Kiyoshi Fukunaga; Yukio Morishita; Nobuhiro Ohkohchi
Journal:  Cancer Sci       Date:  2013-06-24       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.